MannKind
MannKind Corporation is dedicated to developing and commercializing innovative therapeutic products and devices for people with endocrine and orphan lung diseases. Driven by cutting-edge technology and solutions-oriented scientists and medical professionals, the company aims to help people live life more humann. Their focus includes inhaled insulin and other inhalation technologies to improve patient outcomes. MannKind actively engages in clinical trials, collaborates with pharmaceutical organizations, and publishes research to advance treatments, with ongoing research into inhaled therapies for diabetes and lung diseases.
Industries
Nr. of Employees
large (251-1000)
MannKind
1 Casper Street, Danbury, CT 06810
Patents
Products
Commercial inhaled insulin powder product
A marketed rapid‑acting inhaled insulin powder indicated for mealtime glycemic control in adults and under pediatric clinical evaluation.
Dry powder inhalation delivery platform (licensed)
A dry powder carrier and inhalation device platform offered for licensing to formulate and deliver therapeutics via inhalers across a range of molecular weights and drug‑loading conditions.
Wearable preset subcutaneous delivery device
A patch‑style preset infusion device providing continuous subcutaneous medication delivery for defined durations, intended to simplify dosing regimens.
Clinical‑stage inhaled antibiotic formulation (pulmonary suspension)
Pulmonary suspension formulation in clinical development for nontuberculous mycobacterial lung disease; program has progressed through early clinical studies with regulatory interactions supporting expedited development.
Dry powder inhalation antifibrotic candidate (early clinical)
Dry powder inhalation formulation of an antifibrotic agent developed for pulmonary fibrotic diseases; completed Phase 1 demonstrating safety and PK prior to further regulatory engagement.
Commercial inhaled insulin powder product
A marketed rapid‑acting inhaled insulin powder indicated for mealtime glycemic control in adults and under pediatric clinical evaluation.
Dry powder inhalation delivery platform (licensed)
A dry powder carrier and inhalation device platform offered for licensing to formulate and deliver therapeutics via inhalers across a range of molecular weights and drug‑loading conditions.
Wearable preset subcutaneous delivery device
A patch‑style preset infusion device providing continuous subcutaneous medication delivery for defined durations, intended to simplify dosing regimens.
Clinical‑stage inhaled antibiotic formulation (pulmonary suspension)
Pulmonary suspension formulation in clinical development for nontuberculous mycobacterial lung disease; program has progressed through early clinical studies with regulatory interactions supporting expedited development.
Dry powder inhalation antifibrotic candidate (early clinical)
Dry powder inhalation formulation of an antifibrotic agent developed for pulmonary fibrotic diseases; completed Phase 1 demonstrating safety and PK prior to further regulatory engagement.
Services
Protocol design, site coordination, safety and efficacy data analysis, and regulatory submission support for inhaled therapeutic programs including pediatric studies.
Technology licensing, fast feasibility assessments to prepare test powders, animal delivery evaluation, and consolidated technical reporting for partner molecules.
On‑site clinical manufacturing suites, pilot formulation plant, ISO 8 cleanrooms, cartridge production capacity and packaging development services for inhaled drug–device products; offers contract manufacturing for partner products.
Support for regulatory interactions, preparation of filings and coordination of meetings with health authorities to pursue expedited pathways and international approvals.
Protocol design, site coordination, safety and efficacy data analysis, and regulatory submission support for inhaled therapeutic programs including pediatric studies.
Technology licensing, fast feasibility assessments to prepare test powders, animal delivery evaluation, and consolidated technical reporting for partner molecules.
On‑site clinical manufacturing suites, pilot formulation plant, ISO 8 cleanrooms, cartridge production capacity and packaging development services for inhaled drug–device products; offers contract manufacturing for partner products.
Support for regulatory interactions, preparation of filings and coordination of meetings with health authorities to pursue expedited pathways and international approvals.
Expertise Areas
- Pulmonary drug delivery and inhalation formulation
- Clinical trial management for pediatric and adult populations
- GMP clinical and commercial manufacturing for inhaled drug–device products
- Regulatory strategy, expedited pathways and multi‑jurisdictional submissions
Key Technologies
- Dry powder inhalation formulations
- Breath‑actuated and cartridge‑based inhaler engineering
- Spray drying
- Lyophilization
News & Updates
MannKind to highlight data from recent pediatric and adult studies of inhaled insulin (Afrezza®) at the conference.
MannKind to present at the upcoming investor conference.
MannKind to hold the 2025 first quarter financial results conference call.
MannKind reports first quarter 2025 financial results and provides business update.
MannKind collaborates with racing driver Conor Daly to promote diabetes awareness.
MannKind presents efficacy, safety, and mealtime control data from recent pediatric and adult studies of Afrezza®.
MannKind to highlight data from recent pediatric and adult studies of inhaled insulin (Afrezza®) at the conference.
MannKind to present at the upcoming investor conference.
MannKind to hold the 2025 first quarter financial results conference call.
MannKind reports first quarter 2025 financial results and provides business update.
MannKind collaborates with racing driver Conor Daly to promote diabetes awareness.
MannKind presents efficacy, safety, and mealtime control data from recent pediatric and adult studies of Afrezza®.